Stem definition | Drug id | CAS RN |
---|---|---|
Hepatitis Virus C (HVC) protease inhibitors | 5081 | 1350514-68-9 |
Dose | Unit | Route |
---|---|---|
0.10 | g | O |
None
Date | Agency | Company | Orphan |
---|---|---|---|
Jan. 28, 2016 | FDA | MERCK SHARP DOHME |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Pancreas transplant rejection | 79.82 | 53.50 | 7 | 8 | 136 | 56291916 |
None
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Pancreas transplant rejection | 73.79 | 68.90 | 7 | 12 | 307 | 70928118 |
None
Source | Code | Description |
---|---|---|
ATC | J05AP11 | ANTIINFECTIVES FOR SYSTEMIC USE ANTIVIRALS FOR SYSTEMIC USE DIRECT ACTING ANTIVIRALS Antivirals for treatment of HCV infections |
ATC | J05AP54 | ANTIINFECTIVES FOR SYSTEMIC USE ANTIVIRALS FOR SYSTEMIC USE DIRECT ACTING ANTIVIRALS Antivirals for treatment of HCV infections |
MeSH PA | D000890 | Anti-Infective Agents |
MeSH PA | D000998 | Antiviral Agents |
CHEBI has role | CHEBI:36044 | antiviral drugs |
CHEBI has role | CHEBI:62868 | hepatoprotective agents |
CHEBI has role | CHEBI:64924 | hepatitis C protease inhibitors |
Disease | Relation | SNOMED_ID | DOID |
---|---|---|---|
Chronic hepatitis C | indication | 128302006 |
None
None
Dissociation level | Dissociation constant | Type (acidic/basic) |
---|---|---|
pKa1 | 4.1 | acidic |
pKa2 | 1.52 | Basic |
Formulation strength | Trade name | Applicant | Application number | Approval date | Type | Dose form | Route | Patent number | Patent expiration date | Patent use |
---|---|---|---|---|---|---|---|---|---|---|
50MG;100MG | ZEPATIER | MSD SUB MERCK | N208261 | Jan. 28, 2016 | RX | TABLET | ORAL | 7973040 | July 24, 2029 | TREATMENT OF PATIENTS INFECTED WITH HEPATITIS C VIRUS |
50MG;100MG | ZEPATIER | MSD SUB MERCK | N208261 | Jan. 28, 2016 | RX | TABLET | ORAL | 8871759 | May 4, 2031 | TREATMENT OF PATIENTS INFECTED WITH HEPATITIS C VIRUS |
Formulation strength | Trade name | Applicant | Application number | Approval date | Type | Dose form | Route | Exclusivity date | Description |
---|---|---|---|---|---|---|---|---|---|
50MG;100MG | ZEPATIER | MSD SUB MERCK | N208261 | Jan. 28, 2016 | RX | TABLET | ORAL | Dec. 9, 2024 | NEW PATIENT POPULATION |
Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
---|---|---|---|---|---|---|---|---|---|
Genome polyprotein | Polyprotein | INHIBITOR | EC50 | 12.30 | DRUG LABEL | DRUG LABEL | |||
Genome polyprotein | Polyprotein | INHIBITOR | EC50 | 12.40 | DRUG LABEL | DRUG LABEL | |||
Genome polyprotein | Polyprotein | INHIBITOR | EC50 | 12.52 | DRUG LABEL | DRUG LABEL | |||
NS3 | Enzyme | Ki | 10.40 | CHEMBL | |||||
Genome polyprotein | Unclassified | Ki | 10.40 | CHEMBL | |||||
Genome polyprotein | Unclassified | Ki | 9.85 | CHEMBL | |||||
NS3 protease | Unclassified | IC50 | 10.15 | CHEMBL |
ID | Source |
---|---|
4O2AB118LA | UNII |
D10639 | KEGG_DRUG |
1350462-55-3 | SECONDARY_CAS_RN |
C4080053 | UMLSCUI |
CHEBI:132975 | CHEBI |
SUE | PDB_CHEM_ID |
CHEMBL3039533 | ChEMBL_ID |
CHEMBL2063090 | ChEMBL_ID |
44603531 | PUBCHEM_CID |
DB11575 | DRUGBANK_ID |
C578009 | MESH_SUPPLEMENTAL_RECORD_UI |
11573 | IUPHAR_LIGAND_ID |
1734630 | RXNORM |
31483 | MMSL |
d08417 | MMSL |
016674 | NDDF |
716041004 | SNOMEDCT_US |
816104003 | SNOMEDCT_US |
4035374 | VANDF |
None